Brief: Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

Incannex Healthcare

28/02/2024 12:39

Feb 28 (Reuters) - Incannex Healthcare Inc  IXHL.O :
    * INCANNEX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2
PSI-GAD1 CLINICAL TRIAL OF PSILOCYBIN IN GENERALISED ANXIETY
DISORDER
    * INCANNEX HEALTHCARE INC - PSIGAD1 TRIAL ACHIEVES PRIMARY
ENDPOINT
    * INCANNEX HEALTHCARE INC - PSIGAD PSILOCYBIN-ASSISTED
THERAPY
DEMONSTRATED A STATISTICALLY SIGNIFICANT HAM-A REDUCTION OF 12.8
POINTS FROM BASELINE
    * INCANNEX HEALTHCARE - NEWLY DEVELOPED AND FORMULATED
PSX-001
PSILOCYBIN DRUG PRODUCT FINALISED - CGMP MANUFACTURE FOR
CLINICAL TRIAL SUPPLY UNDERWAY
    * INCANNEX HEALTHCARE INC - O SUBMIT AN INVESTIGATIONAL NEW
DRUG
(IND) APPLICATION WITH U.S. FDA TO PROCEED TO A MULTI-SITE PHASE
2B TRIAL
    * INCANNEX HEALTHCARE - 44% OF PATIENTS IN PSILOCYBIN GROUP
AHOWED
AT LEAST 50% REDUCTION IN ANXIETY SCORE AND 27% OF PATIENTS
SHOWED DISEASE REMISSION

Source text for Eikon:  ID:nGNX8pQMLS 
Further company coverage:  IXHL.O 

 ((Reuters.Briefs@thomsonreuters.com;))